Patents by Inventor Mark A. Reid
Mark A. Reid has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240116037Abstract: The present disclosure relates to a coated filter for filtering particulate matter from exhaust gases. The filter has a porous catalyst composition coating, said catalyst composition comprises a zeolite, copper and manganese. The present disclosure also relates to a method forming the coated filter as described herein and an exhaust system with a coated filter as described herein.Type: ApplicationFiled: September 29, 2023Publication date: April 11, 2024Inventors: Francesco FOSCHI, Hannah NOORIZADEH, Stuart REID, Keimoy ST HILL, Mark WALTON, Thilanka WIJEMANNE
-
Patent number: 11564988Abstract: The present invention provides soluble single wall nanotube (SWNT) constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble SWNT via a DNA or other oligomer platform attached to the SWNT. These soluble SWNT constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble SWNT constructs.Type: GrantFiled: September 9, 2019Date of Patent: January 31, 2023Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: David A. Scheinberg, Michael R. McDevitt, Christophe Antczak, Debjit Chattopadhyay, Rena May, Jon Njardarson, Mark Reid Phillips
-
Publication number: 20220387768Abstract: A balloon catheter is provided with a main tube and an air tube therein. The main tube is provided with a central lumen to allow the balloon catheter to travel across and be guided along a guidewire during insertion into a vasculature of a patient. The air tube is configured to transfer fluid, such as air, to a balloon for inflating and deflating the balloon. The air tube can be embedded within the inner and outer surfaces of the main tube. Holes are cut into the main tube and a portion of the air tube to expose the air tube to the environment outside of the main tube. The holes allow for fluid communication between the air tube and the balloon. The holes are cut or sheared at a direction that is lateral to the longitudinal direction of the catheter tube.Type: ApplicationFiled: June 4, 2021Publication date: December 8, 2022Inventors: Mark REID, Andrew ENGLISH, Orlagh MCNALLY, Kyle FLANAGAN
-
Patent number: 11219616Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV1-4 viral infections.Type: GrantFiled: December 23, 2019Date of Patent: January 11, 2022Assignees: 60 Degrees Pharmaceuticals, LLC, National University of Singapore, Singapore Health Services PTE Ltd.Inventors: Geoffrey S. Dow, Subhash Vasudevan, Mark Reid, Glynn Morrish, Cynthia Sung, Abhay Rathore, Satoru Watanabe, Eng Eong Ooi, Jenny Low
-
Publication number: 20200338050Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV1-4 viral infections.Type: ApplicationFiled: December 23, 2019Publication date: October 29, 2020Applicants: 60 Degrees Pharmaceuticals, LLC, National University of Singapore, Singapore Health Services PTE Ltd.Inventors: Geoffrey S. Dow, Subhash Vasudevan, Mark Reid, Glynn Morrish, Cynthia Sung, Abhay Rathore, Satoru Watanabe, Eng Eong Ooi, Jenny Low
-
Publication number: 20200061196Abstract: The present invention provides soluble single wall nanotube (SWNT) constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble SWNT via a DNA or other oligomer platform attached to the SWNT. These soluble SWNT constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble SWNT constructs.Type: ApplicationFiled: September 9, 2019Publication date: February 27, 2020Applicant: Sloan-Kettering Institute for Cancer ResearchInventors: David A. Scheinberg, Michael R. McDevitt, Christophe Antczak, Debjit Chattopadhyay, Rena May, Jon Njardarson, Mark Reid Phillips
-
Patent number: 10517854Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV 1-4 viral infections.Type: GrantFiled: September 18, 2017Date of Patent: December 31, 2019Assignees: 60 Degrees Pharmaceuticals LLC, National University of Singapore, Singapore Health Services PTE Ltd.Inventors: Geoffrey S. Dow, Subhash Vasudevan, Mark Reid, Glynn Morrish, Cynthia Sung, Abhay Rathore, Satoru Watanabe, Eng Eong Ooi, Jenny Low
-
Patent number: 10406236Abstract: The present invention provides soluble single wall nanotube (SWNT) constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble SWNT via a DNA or other oligomer platform attached to the SWNT. These soluble SWNT constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble SWNT constructs.Type: GrantFiled: April 24, 2017Date of Patent: September 10, 2019Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: David A. Scheinberg, Michael R. McDevitt, Christophe Antczak, Debjit Chattopadhyay, Rena May, Jon Njardarson, Mark Reid Phillips
-
Publication number: 20180064693Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I):A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV-4 viral infections.Type: ApplicationFiled: September 18, 2017Publication date: March 8, 2018Applicants: 60 Degrees Pharmaceuticals, LLC, National University of Singapore, Singapore Health Services PTE Ltd.Inventors: Geoffrey S. Dow, Subhash Vasudevan, Mark Reid, Glynn Morrish, Cynthia Sung, Abhay Rathore, Satoru Watanabe, Eng Eong OOI, Jenny Low
-
Publication number: 20170297912Abstract: The present invention provides soluble single wall nanotube (SWNT) constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble SWNT via a DNA or other oligomer platform attached to the SWNT. These soluble SWNT constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble SWNT constructs.Type: ApplicationFiled: April 24, 2017Publication date: October 19, 2017Applicant: Sloan-Kettering Institute for Cancer ResearchInventors: David A. Scheinberg, Michael R. McDevitt, Christophe Antczak, Debjit Chattopadhyay, Rena May, Jon Njardarson, Mark Reid Phillips
-
Patent number: 9763921Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV1-4 viral infections.Type: GrantFiled: March 14, 2014Date of Patent: September 19, 2017Assignees: 60 Degrees Pharmaceuticals LLC, Singapore Health Services PTE LTD, National University Of SingaporeInventors: Geoffrey S. Dow, Subhash Vasudevan, Mark Reid, Glynn Morrish, Cynthia Sung, Abhay Rathore, Satoru Watanabe, Eng Eong Ooi, Jenny Low
-
Patent number: 9629927Abstract: The present invention provides soluble single wall nanotube (SWNT) constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble SWNT via a DNA or other oligomer platform attached to the SWNT. These soluble SWNT constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble SWNT constructs.Type: GrantFiled: September 23, 2013Date of Patent: April 25, 2017Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: David A. Scheinberg, Michael R. McDevitt, Christophe Antczak, Debjit Chattopadhyay, Rena May, Jon Njardarson, Mark Reid Phillips
-
Publication number: 20160030403Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV1-4 viral infections.Type: ApplicationFiled: March 14, 2014Publication date: February 4, 2016Applicants: 60 Degrees Pharmaceuticals, LLC, National University of Singapore, Singapore Health Services PTE Ltd.Inventors: Geoffrey S. DOW, Subhash VASUDEVAN, Mark REID, Glynn MORRISH, Cynthia SUNG, Abhay RATHORE, Satoru WATANABE, Eng Eong OOI, Jenny LOW
-
Patent number: 8729274Abstract: The present invention relates to a tricyclic heterocyclic derivative according to Formula (I), wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to pharmaceutical compositions comprising said tricyclic heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of serotonin mediated disorders, such as obesity.Type: GrantFiled: March 9, 2010Date of Patent: May 20, 2014Assignee: Merck Sharp & Dohme B.V.Inventors: Keneth Davies, Takao Kiyoi, Ashvinkumar Dhirubhai Mistry, Peter Christopher Ray, Mark Reid, Grant Wishart
-
Publication number: 20140086831Abstract: The present invention provides soluble single wall nanotube (SWNT) constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble SWNT via a DNA or other oligomer platform attached to the SWNT. These soluble SWNT constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble SWNT constructs.Type: ApplicationFiled: September 23, 2013Publication date: March 27, 2014Inventors: David A. Scheinberg, Michael R. McDevitt, Christophe Antczak, Debjit Chattopadhyay, Rena May, Jon Njardarson, Mark Reid Phillips
-
Patent number: 8540965Abstract: The present invention provides soluble single wall nanotube constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble single wall carbon nanotube via a DNA or other oligomer platform attached to the single wall carbon nanotube. These soluble single wall carbon nanotube constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble single wall carbon nanotube constructs.Type: GrantFiled: July 31, 2006Date of Patent: September 24, 2013Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: David A. Scheinberg, Michael McDevitt, Christophe Antczak, Debjit Chattopadhyay, Rena May, Jón Njardarson, Mark Reid Philips
-
Publication number: 20120284467Abstract: A data storage system stores logical data object(s), each identified by a logical identifier. A control is configured to assign a unique WORM (Write Once Read Many) identifier to the logical data object, and stores the unique WORM identifier as associated with the logical identifier, in a database maintained by the control so as to be persistent. Data storage is configured to write the logical data object with a header with the unique WORM identifier. The control, in order to allow the logical data object to be accessed externally to the control, requires matching the unique WORM identifier in the header of a logical data object to the unique WORM identifier of the persistent database for the logical object. The unique WORM identifier is formed of a checksum hash value related to nonce fields comprising at least the logical identifier of the logical data object, and an incrementing token.Type: ApplicationFiled: July 18, 2012Publication date: November 8, 2012Applicant: INTERNATIONAL BUSINESS MACHINES CORPORATIONInventors: THOMAS W. BISH, JONATHAN W. PEAKE, MARK A. REID, JOSEPH M. SWINGLER
-
Publication number: 20120232122Abstract: The present invention relates to a tricyclic heterocyclic derivative according to Formula (I), wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to pharmaceutical compositions comprising said tricyclic heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of serotonin mediated disorders, such as obesity.Type: ApplicationFiled: March 9, 2010Publication date: September 13, 2012Inventors: Keneth Davies, Takao Kiyoi, Ashvinkumar Dhirubhai Mistry, Peter Christopher Ray, Mark Reid, Grant Wishart
-
Publication number: 20120086906Abstract: An apparatus and system for alleviating the symptoms of scotopic sensitivity syndrome for a user wearing eyeglasses is provided. The eyewear comprises one or more layers, a first band, and a second band. Each of the layers comprises a coloured film. The first and second bands are attached to the one or more layers. When the eyewear is in use, the one or more layers are placed in front of the eyeglasses and the first band is attached to the second band at a location behind the user's head. Systems for assisting in viewing a computer screen or printed matter are also provided.Type: ApplicationFiled: October 7, 2011Publication date: April 12, 2012Inventor: Mark Reid
-
Publication number: 20110107024Abstract: A data storage system stores logical data object(s), each identified by a logical identifier. A control is configured to assign a unique WORM (Write Once Read Many) identifier to the logical data object, and stores the unique WORM identifier as associated with the logical identifier, in a database maintained by the control so as to be persistent. Data storage is configured to write the logical data object with a header with the unique WORM identifier. The control, in order to allow the logical data object to be accessed externally to the control, requires matching the unique WORM identifier in the header of a logical data object to the unique WORM identifier of the persistent database for the logical object. The unique WORM identifier is formed of a checksum hash value related to nonce fields comprising at least the logical identifier of the logical data object, an incrementing token, and a time stamp.Type: ApplicationFiled: November 4, 2009Publication date: May 5, 2011Applicant: INTERNATIONAL BUSINESS MACHINES CORPORATIONInventors: THOMAS W. BISH, Jonathan W. Peake, Mark A. Reid, Joseph M. Swingler